Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Bitcoin Trust (IBIT) vs Pfizer Inc (PFE) Price & Performance

iShares Bitcoin TrustTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares Bitcoin Trust vs Pfizer Inc — how do they compare? iShares Bitcoin Trust trades at $37.53, while Pfizer Inc trades at $24.77 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares Bitcoin Trust pays none, and Pfizer Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.

IBITPFE
Sector
Crypto-linkedHealth
52-Week High
$71.29$28.56
52-Week Low
$33.29$23.29
Market Cap
$141.06B
Volume
29,869,932
Enterprise Value
$191.72B
Dividend Yield
6.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Bitcoin Trust

IBIT trades at $36.89, up 1.49% with neutral technical signals. The stock shows mixed momentum with bearish moving averages but neutral oscillators. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing Fidelity's competing fund. The ETF faces headwinds from significant outflows in June 2026 but maintains institutional interest as a preferred Bitcoin exposure vehicle.

Outlook remains cautious amid Bitcoin market volatility and ETF outflow pressures. Investment opportunity lies in IBIT's dominant market position and institutional adoption, balanced against cryptocurrency market risks and competitive ETF landscape. Key risks include Bitcoin price sensitivity and regulatory uncertainty affecting fund flows.

Pfizer Inc

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.

The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Bitcoin Trust

IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.

Read more on IBIT

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE